An Israeli biotech firm says it is nearing human trials for a breakthrough drug that could extend human lifespan by up to 30 percent by targeting the age-regulating protein SIRT-6, which the company says would also improve brain function, organ health, and overall vitality. On Friday, Israeli news site N12 reported that Tel Aviv-based Sirtlab is preparing to launch clinical trials on a drug designed to stimulate SIRT-6, a protein associated with youth, vitality, and disease resistance. The treatment could be available within three years, pending successful trials and regulatory approval. Professor Haim Cohen, the company’s chief scientist and head...